STOCK TITAN

Masimo to Present in Stifel Virtual Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Masimo (NASDAQ: MASI) is set to present at the Stifel Virtual Healthcare Conference on November 17, 2020, at 2:40 p.m. Eastern Time. Live access to the presentation will be available via webcast on the Masimo website, with a replay offered afterward. Known for its advanced medical monitoring technologies, Masimo’s innovations, such as SET pulse oximetry, have significantly improved patient outcomes and reduced healthcare costs. The company’s products are used globally, impacting over 100 million patients and assisting healthcare professionals in critical care scenarios.

Positive
  • None.
Negative
  • None.

IRVINE, Calif.--()--Masimo (NASDAQ: MASI) today announced that its management is scheduled to participate in the Stifel Virtual Healthcare Conference on Tuesday, November 17, 2020 at 2:40 p.m. Eastern Time. A live webcast of the presentation will be available on the Masimo website at www.masimo.com. A replay of the webcast will be available following the live presentation.

About Masimo

Masimo (Nasdaq: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. Our mission is to improve patient outcomes and reduce the cost of care. Masimo SET® Measure-through Motion and Low Perfusion pulse oximetry, introduced in 1995, has been shown in over 100 independent and objective studies to outperform other pulse oximetry technologies. Masimo SET® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates, improve CCHD screening in newborns, and, when used for continuous monitoring with Masimo Patient SafetyNet in post-surgical wards, reduce rapid response team activations, ICU transfers, and costs. Masimo SET® is estimated to be used on more than 100 million patients in leading hospitals and other healthcare settings around the world, and is the primary pulse oximetry at 9 of the top 10 hospitals listed in the 2018-19 U.S. News and World Report Best Hospitals Honor Roll.8 Masimo continues to refine SET® and in 2018, announced that SpO2 accuracy on RD SET sensors during conditions of motion has been significantly improved, providing clinicians with even greater confidence that the SpO2 values they rely on accurately reflect a patient’s physiological status. In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVi®), RPVi (rainbow® PVi), and Oxygen Reserve Index (ORi). In 2013, Masimo introduced the Root® Patient Monitoring and Connectivity Platform, built from the ground up to be as flexible and expandable as possible to facilitate the addition of other Masimo and third-party monitoring technologies; key Masimo additions include Next Generation SedLine® Brain Function Monitoring, O3® Regional Oximetry, and ISA Capnography with NomoLine® sampling lines. Masimo’s family of continuous and spot-check monitoring Pulse CO-Oximeters® includes devices designed for use in a variety of clinical and non-clinical scenarios, including tetherless, wearable technology, such as Radius-7® and Radius PPG, portable devices like Rad-67, fingertip pulse oximeters like MightySat® Rx, and devices available for use both in the hospital and at home, such as Rad-97. Masimo hospital automation and connectivity solutions are centered around the Iris® platform, and include Iris Gateway, Patient SafetyNet, Replica, Halo ION, UniView, and Doctella. Additional information about Masimo and its products may be found at www.masimo.com. Published clinical studies on Masimo products can be found at www.masimo.com/evidence/featured-studies/feature/.

Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care... by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI and ORI are trademarks or registered trademarks of Masimo Corporation

Contacts

Investor Contact: Eli Kammerman
(949) 297-7077
ekammerman@masimo.com

Media Contact: Evan Lamb
(949) 396-3376
elamb@masimo.com

FAQ

When is Masimo's presentation at the Stifel Virtual Healthcare Conference?

Masimo's presentation is scheduled for November 17, 2020, at 2:40 p.m. Eastern Time.

How can I access Masimo's presentation at the Stifel Virtual Healthcare Conference?

You can access the live webcast of Masimo's presentation on their official website.

What is the significance of Masimo's Set pulse oximetry technology?

Masimo's SET pulse oximetry technology has been proven to outperform other technologies and is utilized in over 100 million patients worldwide.

What innovations does Masimo offer in the medical technology field?

Masimo offers advanced monitoring technologies, including pulse oximetry, patient monitoring, and connectivity solutions, enhancing patient care and outcomes.

Where can I find a replay of Masimo's conference presentation?

A replay of Masimo's conference presentation will be available on their website following the live presentation.

Masimo Corporation

NASDAQ:MASI

MASI Rankings

MASI Latest News

MASI Stock Data

9.12B
49.16M
8.19%
94.77%
6.24%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States of America
IRVINE